HA-Irinotecan

Currently in a pivotal Phase III trial in mCRC with top line data expected in H1-CY 2014.


Products

Audeo Oncology manages a late-stage oncology pipeline which includes HA-Irinotecan in Phase III clinical trial


HyACT

HyACT is a flexible platform technology that we are using to target cancer drugs directly to tumors. More...


Contact

Wants more information about Audeo, our products or investing?